All In Biotech

Drug Trial Radar · NCT06922591

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

183

Planned (sponsor's estimate)

Start

May 31, 2025

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Tango Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Revolution Medicines, Inc.
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Conditions

  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • RAS Mutation
  • MTAP Deletion
  • Lung Cancer
  • Pancreatic Cancer Metastatic
  • Thoracic Cancer

Interventions

  • TNG462Drug

    MTA cooperative PRMT5 inhibitor

  • RMC-9805Drug

    RAS(ON) G12D selective covalent inhibitor

  • RMC-6236Drug

    RAS(ON) multi-selective inhibitor

  • mFOLFIRINOXDrug

    Chemotherapy

  • gemcitabine/nab-paclitaxelDrug

    Chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Maximum Tolerated DoseTime frame: 21 days
  2. Phase 1: Maximum Tolerated DoseTime frame: 28 days
  3. Phase 2: Combination Anti-neoplastic ActivityTime frame: 12 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona · Recruiting

  • Sarah Cannon Research Institute Denver

    Denver, Colorado · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • University of Indiana

    Indianapolis, Indiana · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Cancer Center

    Rochester, Minnesota · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.